Swinkels O Q J, Prins M, Kucharekova M, de Boo T, Gerritsen M J P, van der Valk P G M, van de Kerkhof P C M
Department of Dermatology, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.
Br J Dermatol. 2002 Apr;146(4):621-6. doi: 10.1046/j.1365-2133.2002.04698.x.
Since its introduction, the effectiveness of dithranol in treating psoriasis has been unequalled by other topical treatments. Out-patient short-contact dithranol treatment is effective with regard to clinical response rate and relapse rate after 1 year. A drawback, however, is the relatively long treatment duration.
To study a dithranol regimen combined with a potent topical corticosteroid with regard to clinical response rate, treatment duration and remission period after clearance.
Twelve patients with stable psoriasis vulgaris participated in this study. We treated three comparable psoriasis lesions on the extremities for 39 consecutive days. The first lesion was treated daily with short-contact dithranol cream followed by clobetasol-17-propionate ointment 5 days per week. The second lesion was treated daily with short-contact dithranol cream followed by the vehicle of clobetasol-17-propionate ointment. The third lesion was treated with clobetasol-17-propionate ointment 5 days per week. The patients attended on days 1, 4, 9, 12, 15, 18, 22, 25, 32 and 39 during treatment. We assessed lesional severity scores at each visit and registered the baseline area at the first visit. During the follow up at weeks 2, 4, 6, 10, 14, 19 and 23 we assessed lesional sum scores. We also estimated the area involved in recurrence of the lesion as a percentage of the baseline area. The overall differences between the three treatment curves for the treatment period and follow-up period separately were tested with a likelihood ratio test.
Differences between the curves of the sum scores during treatment (P < 0.001) were mainly due to the different time-course of dithranol monotherapy, which showed a slower decrease in sum score. Differences between the linear trends of the sum score (P < 0.001) and the area score P < 0.001) during follow up were due to a different time-course of the combination therapy, which started lower and increased more slowly, suggesting a slower relapse rate with combination therapy. When comparing the follow-up data, it must be kept in mind that the three treatments showed an overall significantly different sum and area score at the start of follow up.
Intermittent addition of clobetasol-17-propionate ointment enhanced the antipsoriatic efficacy of short-contact, high-dose dithranol therapy in terms of clearing capacity and treatment duration, without shortening remission duration.
自引入以来,地蒽酚治疗银屑病的有效性是其他局部治疗无法比拟的。门诊短期接触地蒽酚治疗在临床缓解率和1年后的复发率方面是有效的。然而,一个缺点是治疗持续时间相对较长。
研究一种地蒽酚方案联合一种强效局部皮质类固醇在临床缓解率、治疗持续时间和清除后的缓解期方面的效果。
12例寻常型银屑病稳定期患者参与了本研究。我们连续39天对四肢上三个类似的银屑病皮损进行治疗。第一个皮损每天用短期接触地蒽酚乳膏治疗,随后每周5天使用丙酸氯倍他索软膏。第二个皮损每天用短期接触地蒽酚乳膏治疗,随后使用丙酸氯倍他索软膏的基质。第三个皮损每周5天用丙酸氯倍他索软膏治疗。患者在治疗期间的第1、4、9、12、15、18、22、25、32和39天前来就诊。我们在每次就诊时评估皮损严重程度评分,并在首次就诊时记录基线面积。在第2、4、6、10、14、19和23周的随访期间,我们评估皮损总分。我们还估计皮损复发所累及的面积占基线面积的百分比。分别用似然比检验对治疗期和随访期三条治疗曲线之间的总体差异进行检验。
治疗期间总分曲线之间的差异(P<0.001)主要是由于地蒽酚单一疗法的不同时间进程,其总分下降较慢。随访期间总分(P<0.001)和面积评分(P<0.001)线性趋势之间的差异是由于联合疗法的不同时间进程,联合疗法开始时较低且增加较慢,表明联合疗法的复发率较低。在比较随访数据时,必须记住,三种治疗在随访开始时的总分和面积评分总体上有显著差异。
间歇性添加丙酸氯倍他索软膏在清除能力和治疗持续时间方面增强了短期接触、高剂量地蒽酚疗法的抗银屑病疗效,而不会缩短缓解期。